Aldeyra Therapeutics, Inc. (FRA:137)
Germany
· Delayed Price · Currency is EUR 4.011
-0.145 (-3.49%)
At close: Dec 5, 2025
Aldeyra Therapeutics Statistics
Total Valuation
FRA:137 has a market cap or net worth of EUR 243.06 million. The enterprise value is 191.70 million.
| Market Cap | 243.06M |
| Enterprise Value | 191.70M |
Important Dates
The next estimated earnings date is Thursday, March 5, 2026.
| Earnings Date | Mar 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
| Current Share Class | 60.16M |
| Shares Outstanding | n/a |
| Shares Change (YoY) | +0.88% |
| Shares Change (QoQ) | +0.14% |
| Owned by Insiders (%) | 3.14% |
| Owned by Institutions (%) | 48.31% |
| Float | 47.58M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 5.79 |
| P/TBV Ratio | 5.79 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.21 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 2.72, with a Debt / Equity ratio of 0.32.
| Current Ratio | 2.72 |
| Quick Ratio | 2.64 |
| Debt / Equity | 0.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -23.76 |
Financial Efficiency
Return on equity (ROE) is -64.31% and return on invested capital (ROIC) is -34.12%.
| Return on Equity (ROE) | -64.31% |
| Return on Assets (ROA) | -28.94% |
| Return on Invested Capital (ROIC) | -34.12% |
| Return on Capital Employed (ROCE) | -91.60% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -4.60M |
| Employee Count | 9 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -6.65% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -6.65% |
| 50-Day Moving Average | 4.44 |
| 200-Day Moving Average | 3.93 |
| Relative Strength Index (RSI) | 39.20 |
| Average Volume (20 Days) | 218 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 7.43 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -38.50M |
| Pretax Income | -36.81M |
| Net Income | -36.81M |
| EBITDA | -38.29M |
| EBIT | -38.50M |
| Earnings Per Share (EPS) | -0.61 |
Balance Sheet
The company has 64.18 million in cash and 13.25 million in debt, giving a net cash position of 50.93 million.
| Cash & Cash Equivalents | 64.18M |
| Total Debt | 13.25M |
| Net Cash | 50.93M |
| Net Cash Per Share | n/a |
| Equity (Book Value) | 41.97M |
| Book Value Per Share | 0.70 |
| Working Capital | 41.74M |
Cash Flow
| Operating Cash Flow | -34.16M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
FRA:137 does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.88% |
| Shareholder Yield | -0.88% |
| Earnings Yield | -15.15% |
| FCF Yield | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |